List of Excipients in Branded Drug MAXALT-MLT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	MAXALT-MLT	rizatriptan benzoate	16590-144	ASPARTAME
STAT RX USA LLC	MAXALT-MLT	rizatriptan benzoate	16590-144	GELATIN
STAT RX USA LLC	MAXALT-MLT	rizatriptan benzoate	16590-144	GLYCINE
STAT RX USA LLC	MAXALT-MLT	rizatriptan benzoate	16590-144	MANNITOL

MAXALT-MLT Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

MAXALT-MLT is an orally disintegrating tablet containing rizatriptan benzoate, a 5-HT1B/1D receptor agonist for acute migraine treatment. Its commercial differentiation depends less on the active ingredient, whose core U.S. patent protection has expired, than on excipient selection, taste masking, rapid dispersion, moisture control, packaging, and regulatory equivalence.

The strongest generic and lifecycle opportunities are:

1. A low-cost rizatriptan ODT with a simple mannitol-based platform.
2. A premium ODT with improved taste, lower friability, and better stability.
3. An aspartame-free formulation for patients with phenylketonuria.
4. A pediatric or dysphagia-oriented formulation with optimized mouthfeel.
5. A globally adaptable formulation using excipients accepted across the U.S., European Union, and major emerging markets.

What is MAXALT-MLT and how does its formulation work?

MAXALT-MLT contains rizatriptan benzoate in 5 mg and 10 mg orally disintegrating tablets. The dosage form is designed to disperse on the tongue without water, supporting migraine patients who have nausea, vomiting, or difficulty swallowing conventional tablets.

The labeled inactive ingredients include:

Excipient	Primary formulation role
Mannitol	Diluent, mouthfeel modifier, cooling sensation
Gelatin	Binder and structural matrix for the rapidly dispersing tablet
Glycine	Bulking agent and taste or mouthfeel modifier
Aspartame	Sweetener and bitterness masking
Peppermint flavor	Flavor correction and sensory masking

The formulation does not rely on a conventional high-dose disintegrant system in the same way as many compressed tablets. The product’s performance depends on the interaction of porous or rapidly wettable excipient particles, soluble materials, tablet structure, and packaging protection.

Why the excipient system matters

Rizatriptan has a bitter pharmaceutical taste. In an ODT, the active ingredient is exposed in the mouth before swallowing, making taste masking a central product-quality attribute. A formulation that matches dissolution but has poor palatability may fail to reproduce the commercial value of MAXALT-MLT.

Mannitol is commercially important because it provides:

• Rapid dissolution and a cooling oral sensation.
• Low hygroscopicity compared with many polyols.
• A relatively clean taste profile.
• Compatibility with direct-compression and specialty ODT manufacturing platforms.

Gelatin contributes to tablet integrity and rapid wetting, but it creates animal-origin, vegetarian, religious-compliance, and supply-chain considerations. An alternative polymer or binder may widen market access, but it can alter tablet strength, disintegration, friability, and taste.

Aspartame provides strong sweetness at low loading, but it creates a labeling restriction for patients with phenylketonuria. An aspartame-free product can support a differentiated label and reduce a known patient-use limitation.

What patents protect MAXALT-MLT and rizatriptan?

The core U.S. patent estate for rizatriptan and the original MAXALT product is no longer the principal market barrier. Generic rizatriptan tablets and orally disintegrating tablets have been marketed in the United States, indicating that active-ingredient exclusivity and the principal branded product barriers have expired or ceased to block ANDA competition.

Protection category	MAXALT-MLT position	Commercial implication
Rizatriptan active-ingredient patents	Historical protection expired	No remaining core-molecule barrier to ordinary generic entry
Original product patents	Historical protection expired or became commercially immaterial	Generic ODT development is feasible
Formulation patents	Must be assessed by jurisdiction and claim scope	Potential risk for specific manufacturing or excipient combinations
Method-of-use patents	Migraine-treatment methods have limited blocking value where expired	Label strategy remains important for ANDA applicants
Regulatory exclusivity	No current branded exclusivity is expected to block standard generic development	ANDA pathway is the principal U.S. route
Trade dress and trademarks	MAXALT and MAXALT-MLT remain brand identifiers	Generic products require distinct naming and packaging

A precise current patent determination requires review of the FDA Orange Book, U.S. Patent and Trademark Office records, and active litigation dockets. The commercial evidence is clear: multiple generic rizatriptan products have entered the U.S. market, including orally disintegrating presentations.

Historical patent families associated with rizatriptan include patents covering the triptan chemical class and specific rizatriptan compounds. Those patents are no longer the relevant source of exclusivity for present-day MAXALT-MLT competition. The remaining IP risk is more likely to arise from narrow formulation, manufacturing, or foreign-jurisdiction claims than from the active ingredient.

When did MAXALT-MLT lose exclusivity?

MAXALT was approved by the FDA in 1998. MAXALT-MLT was subsequently approved as an orally disintegrating presentation. The relevant commercial exclusivity period has ended, and generic rizatriptan products are available.

Event	Approximate timing
FDA approval of MAXALT	1998
MAXALT-MLT commercial introduction	Late 1990s
Core rizatriptan patent exclusivity	Expired before current generic competition
Generic rizatriptan entry	2010s market period
Current position	Mature generic market

The historical U.S. market used patent-term extensions and pediatric exclusivity mechanisms that affected the timing of generic entry. Those periods are no longer a current barrier to development.

What is the Orange Book status of MAXALT-MLT?

The Orange Book is the controlling source for listed patents and exclusivity associated with FDA-approved reference products. MAXALT-MLT should be evaluated through the current Orange Book listing under rizatriptan benzoate and the relevant reference-listed drug entries.

The absence of an active blocking patent does not eliminate all litigation exposure. An ANDA applicant can face:

• A Paragraph IV notice concerning a listed formulation or method patent.
• A patent-infringement action under Hatch-Waxman.
• A dispute over the reference-listed drug, dosage form, or listed patent scope.
• A formulation claim directed to an excipient ratio, compression method, or taste-masking process.

What excipient strategy best supports a generic MAXALT-MLT product?

A successful formulation should reproduce the reference product’s critical quality attributes without unnecessarily copying its excipient composition. FDA generic standards focus on pharmaceutical equivalence and bioequivalence, not exact excipient identity, unless a specific excipient materially affects performance or safety.

Strategy 1: Mannitol-based direct-compression ODT

A mannitol-led formulation is the most direct commercial approach. It can use a co-processed ODT excipient or a blend of mannitol with a disintegrant and a low-level binder.

Key development targets include:

• Disintegration within the applicable ODT performance range.
• Adequate tablet hardness for blister packaging.
• Low friability.
• Rapid wetting and dispersion.
• Acceptable bitterness and aftertaste.
• Low moisture uptake.

This approach has a broad supplier base and can support low manufacturing cost. The main risks are capping, lamination, excessive dust, and loss of mechanical strength when the tablet is made highly porous.

Strategy 2: Aspartame-free sweetening system

Replacing aspartame creates a differentiated product for phenylketonuria patients and consumers who avoid synthetic sweeteners. Candidate systems may include sucralose, acesulfame potassium, saccharin, steviol glycosides, or combinations with polyols and flavor modifiers.

The commercial tradeoff is sensory performance. Sweetener replacement can affect:

• Bitterness suppression.
• Onset and duration of sweetness.
• Cooling sensation.
• Residual taste.
• Tablet mass.
• Regulatory labeling.

An aspartame-free product may command limited price premium but can improve formulary and pharmacy substitution appeal if the label is easier for patients to use.

Strategy 3: Gelatin-free ODT

Gelatin-free products address vegetarian, halal, kosher, and animal-origin concerns. Options include modified cellulose, povidone, starch derivatives, pullulan, or other film-forming and binding materials.

The formulation challenge is preserving the reference product’s rapid oral dispersion. A polymer that improves tablet strength may slow wetting or create a gummy mouthfeel. A gelatin-free product therefore requires early evaluation of sensory characteristics, not only standard dissolution.

Strategy 4: Advanced taste masking

Rizatriptan is administered at a low dose, which creates favorable conditions for taste masking. Potential approaches include:

• Drug-resin complexes.
• Polymer coating.
• Ion-exchange systems.
• Microparticles.
• Cyclodextrin complexation.
• pH-adjusted flavor systems.
• Multiparticulate compression.

A taste-masked formulation can support a premium product, but excessive processing may increase cost and create a new patent footprint. It may also change dissolution or bioavailability. For a 505(j) product, the least complex system that meets taste and performance targets is generally the most commercially attractive.

What manufacturing and IP barriers affect MAXALT-MLT competition?

The main barriers are process and quality barriers rather than active-ingredient access.

Moisture management

ODTs are vulnerable to moisture during granulation, compression, storage, and opening by patients. Moisture can cause:

• Loss of tablet hardness.
• Premature disintegration.
• Sticking during compression.
• Excipient recrystallization.
• Flavor migration.
• Degradation or instability of the active ingredient.

Unit-dose aluminum-aluminum blister packaging is often preferable to a conventional multidose bottle. Packaging cost is higher, but it protects the product’s sensory and mechanical attributes.

Compression process

A conventional high-force tablet may resist disintegration. A low-force process may produce fragile tablets. Commercial optimization must balance:

Attribute	Low value risk	High value risk
Compression force	Friability and breakage	Slow disintegration
Porosity	Poor strength	Excessive moisture uptake
Lubricant level	Sticking	Delayed wetting or dissolution
Tablet hardness	Package failures	Poor mouth dispersion
Flavor loading	Weak taste masking	Overpowering sensory profile

Direct compression is attractive because it reduces processing steps and solvent exposure. It can also produce batch-to-batch variability if excipient particle size, flow, or segregation is poorly controlled.

Excipient supply and qualification

Mannitol, specialty ODT excipients, flavors, sweeteners, and packaging materials are available from multiple suppliers, but changes can affect product performance. A robust commercial strategy should qualify at least two sources for critical excipients where practical, with controls for:

• Particle-size distribution.
• Polymorphic form.
• Moisture content.
• Bulk density.
• Flowability.
• Microbial limits.
• Residual solvents.
• Animal-origin status.

Supplier changes can require comparability studies, stability data, and regulatory notification.

What FDA regulatory pathway applies to generic MAXALT-MLT?

A generic rizatriptan ODT would generally use the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The product must address:

• Pharmaceutical equivalence to the reference-listed drug.
• Bioequivalence.
• Same active ingredient and dosage form.
• Equivalent strength.
• Comparable labeling, subject to permitted generic differences.
• Manufacturing compliance under current good manufacturing practice.
• Appropriate control of excipient safety and quality.

For an ODT, the development program should assess more than conventional dissolution. Relevant studies can include:

• Disintegration testing.
• Comparative dissolution across pH conditions.
• Drug-release profiling.
• In vitro dispersion.
• In-use stability after blister removal.
• Comparative moisture sensitivity.
• Sensory or taste evaluation where relevant.
• Human bioequivalence studies under fasting and fed conditions if required by FDA.

FDA’s guidance on orally disintegrating tablets identifies rapid disintegration and ease of administration as central product characteristics. A generic sponsor should avoid assuming that ordinary immediate-release tablet criteria are sufficient for a commercially credible ODT.

Can an excipient change trigger Paragraph IV risk?

An excipient change by itself does not normally create Paragraph IV risk. Paragraph IV litigation concerns a listed patent that the ANDA applicant certifies is invalid, unenforceable, or not infringed.

The risk increases when the formulation uses:

• A patented taste-masking technology.
• A specific excipient ratio claimed in an active patent.
• A protected manufacturing sequence.
• A patented coating or drug-resin complex.
• A process that reproduces a branded formulation claim.

A freedom-to-operate review should therefore separate expired MAXALT-MLT patents from third-party excipient and ODT platform patents.

Which companies are challenging MAXALT-MLT?

The relevant competitive group is the generic rizatriptan market rather than a single branded challenger. U.S. generic products have been marketed by multiple manufacturers and labelers, including companies operating through ANDA ownership, contract manufacturing, or product licensing arrangements.

Competitive intensity is highest in standard 5 mg and 10 mg tablets. The ODT segment has more differentiation potential because it requires specialized formulation, packaging, and sensory development.

Competitor type	Competitive position
Low-cost tablet manufacturers	Strong price pressure, weaker ODT differentiation
Established generic ODT manufacturers	Direct MAXALT-MLT substitutes
Specialty oral-dose companies	Potential premium taste and packaging products
Contract manufacturers	Enable rapid market entry for smaller sponsors
Branded migraine companies	Compete through newer delivery systems and preventive therapies

There is no biosimilar issue. Rizatriptan is a chemically synthesized small molecule, not a biologic. The relevant alternatives are generics, branded triptans, nasal products, injectable products, and newer migraine therapies such as gepants and monoclonal antibodies.

What commercial opportunities exist for MAXALT-MLT excipient innovation?

Patient-centered differentiation

The most practical opportunity is a better patient experience:

• Faster perceived dispersion.
• Less bitterness.
• Lower tablet residue.
• Reduced friability.
• Easier blister opening.
• No water requirement.
• Aspartame-free labeling.
• Gelatin-free composition.

These improvements can support pharmacy and payer adoption even when the active ingredient is commoditized.

Pediatric and adolescent positioning

Rizatriptan has pediatric use in certain age groups and strengths under FDA labeling. A low-mass, easy-to-administer ODT can be commercially useful for adolescents and patients who cannot swallow tablets. Pediatric positioning must remain consistent with the approved label and cannot rely solely on excipient novelty.

Potential development priorities include:

• Reduced tablet size.
• Mild flavor.
• Limited residual sweetness.
• Child-resistant but accessible packaging.
• Avoidance of excipients that create avoidable pediatric concerns.

International expansion

A globally deployable formulation should minimize excipients that create country-specific barriers. Key considerations include:

• Aspartame and phenylalanine labeling.
• Gelatin source and animal-origin certification.
• Colorant restrictions.
• Sweetener acceptance.
• Flavor registration requirements.
• Pharmacopoeial standards.
• Local packaging and humidity conditions.

A formulation based on mannitol, a globally accepted binder or disintegrant, and broadly accepted flavor and sweetener systems may reduce regulatory fragmentation.

Licensing and platform deals

The most defensible licensing opportunities are likely to involve enabling technology rather than the rizatriptan molecule. Potential assets include:

• Proprietary ODT excipient platforms.
• Taste-masking systems.
• Moisture-resistant blister technologies.
• Gelatin-free rapidly dispersing matrices.
• Continuous-compression processes.
• Pediatric sensory platforms.

A licensee will typically value reduced development time, reproducible scale-up, and a clear freedom-to-operate position more than a broad but difficult-to-practice patent claim.

How does MAXALT-MLT compare with other migraine delivery systems?

Product type	Main advantage	Main limitation	Excipient opportunity
Conventional rizatriptan tablet	Lowest manufacturing cost	Requires swallowing and water	Limited differentiation
Rizatriptan ODT	Water-free administration	Taste and moisture sensitivity	High
Rizatriptan oral film	Thin, portable dosage form	Film strength and dose uniformity	Moderate to high
Nasal triptan	Avoids swallowing	Nasal irritation and device complexity	Device and formulation dependent
Injectable triptan	Rapid systemic delivery	Administration burden	Low for excipient-led products
Gepant tablet or ODT	Newer mechanism and market positioning	Higher cost and patent barriers	Potentially high, but protected by newer IP

MAXALT-MLT’s remaining value is dosage-form convenience. It does not have the patent leverage of newer migraine products, so commercial success depends on cost, availability, tolerability, and patient preference.

What generic launch scenarios exist for MAXALT-MLT?

Commodity launch

A sponsor can launch a standard rizatriptan ODT with a conventional mannitol-based formulation and compete on acquisition cost. This strategy requires disciplined manufacturing and efficient packaging but offers limited pricing power.

Differentiated excipient launch

An aspartame-free or gelatin-free ODT can create a distinct product profile. The commercial benefit is likely to come from targeted pharmacy, hospital, and patient channels rather than broad premium pricing.

Platform launch

A sponsor can use rizatriptan as the first product in a broader ODT portfolio. Shared excipient systems, tooling, analytical methods, and packaging can reduce development cost across other low-dose migraine or central-nervous-system products.

Authorized or licensed generic

A brand-linked or licensed generic arrangement can provide distribution access and lower launch risk, but the value depends on manufacturing economics, channel rights, and the absence of restrictive settlement terms.

What patent litigation and settlement risks remain?

The principal historical Hatch-Waxman disputes concerned generic timing and patent certifications surrounding rizatriptan products. For a new entrant, current risk is more likely to involve:

1. A later-issued formulation patent.
2. A third-party ODT technology patent.
3. A process patent covering taste masking or compression.
4. A dispute over whether the proposed product falls within a listed claim.
5. A contract dispute involving a licensed generic or contract manufacturer.

No active settlement should be assumed solely from the existence of prior generic entry. Each ANDA applicant must review current Orange Book listings, patent certifications, litigation records, and any applicable 180-day exclusivity status.

Key Takeaways

• MAXALT-MLT is a rizatriptan benzoate orally disintegrating tablet differentiated by administration convenience.
• Core active-ingredient and historical branded exclusivity barriers have expired, enabling generic competition.
• The principal formulation value lies in mannitol-based mouthfeel, rapid dispersion, taste masking, and moisture protection.
• Aspartame-free and gelatin-free formulations offer the clearest excipient-led differentiation.
• Unit-dose blister packaging is important because ODT performance is sensitive to humidity.
• The FDA 505(j) pathway is the expected route for a generic rizatriptan ODT.
• Biosimilar risk is irrelevant because rizatriptan is a small-molecule drug.
• Remaining IP exposure is more likely to arise from third-party ODT, taste-masking, process, or packaging patents than from the rizatriptan molecule.
• The most attractive commercial strategy is a low-cost, stable, palatable ODT with a clear labeling advantage.

FAQs

Is MAXALT-MLT still patent protected?

The core U.S. patent protection associated with rizatriptan and the original MAXALT product has expired or no longer blocks ordinary generic entry. Current Orange Book listings should control any product-specific assessment.

Can a generic MAXALT-MLT use different excipients?

Yes. A generic may use different inactive ingredients if it satisfies FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality, and labeling.

Is an aspartame-free rizatriptan ODT commercially attractive?

Yes. It can differentiate the product for patients with phenylketonuria or those seeking an aspartame-free medicine, although sensory performance and cost must remain competitive.

Does MAXALT-MLT require a special blister package?

A moisture-protective unit-dose package is commercially important for preserving tablet integrity, rapid disintegration, and stability. Aluminum-aluminum blister packaging is a common high-protection option.

Can rizatriptan be reformulated as an oral film?

Potentially, but an oral film would require new development work for dose uniformity, mechanical strength, taste masking, drying, packaging, and bioequivalence. It may offer convenience but would face stronger manufacturing and intellectual-property complexity than a conventional ODT.

References

1. U.S. Food and Drug Administration. (1998). MAXALT (rizatriptan benzoate) tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). MAXALT-MLT (rizatriptan benzoate) orally disintegrating tablets prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2008). Guidance for industry: Orally disintegrating tablets. FDA.

5. U.S. Food and Drug Administration. (2013). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

6. U.S. National Library of Medicine. (n.d.). Rizatriptan benzoate orally disintegrating tablet drug labels. DailyMed.

7. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.

8. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.